Last reviewed · How we verify
NCT00914537
Anal Cancer Screening Study
trial in Anal Cancer in 363 participants. Completed in 4 November 2020.
4 November 2020
Quick facts
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 363 |
| Start date | 2 June 2009 |
| Primary completion | 4 November 2020 |
| Estimated completion | 4 November 2020 |
| Sites | 1 location across United States |
Conditions studied
- Anal Cancer — all drugs for Anal Cancer →
Sponsor
National Cancer Institute (NCI)
Who can join
Adults 18 to 110, male only, with Anal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: * HIV-positive men who have sex with men (MSM) have rates of anal cancer that approach those of cervical cancer in women. However, unlike cervical cancer, there is no current recommended method of screening that could be used to detect anal precancerous lesions for the prevention of anal cancer in HIV-positive MSM. * Infections by human papillomavirus (HPV) are the likely cause of cervical and anal precancer and cancer. Detecting the presence of HPV or related biomarkers has helped to identify women who may be at increased risk of cervical cancer; researchers believe that early detection of HPV or related biomarkers in MSM may be useful for anal cancer screening. Objectives: \- To evaluate the effectiveness of various tests to detect cancer-causing HPV in HIV-positive men who have sex with men. Eligibility: \- HIV-positive MSM that are interested in receiving anal screening for precancer Design: * HIV-positive MSM will respond to a self-administered risk factor questionnaire, and will undergo a physical exam and a high-resolution anoscopy at the participating clinic. * The clinician will then collect to anal Pap specimens from each subject for research on HPV and related biomarkers. * Participants will be followed annually for 2 years to collect additional health data for research follow-up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00914537
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anal Cancer
Currently open trials in the same condition.
- NCT07192055 — Self-sampling to Optimize Anal Lesion Outcomes · NA · recruiting
- NCT07296237 — Beyond Survival: Addressing Gynecological and Sexual Health in Women After Radiotherapy for Anal Cancer · recruiting
- NCT07124000 — DESTINY-PANTUMOUR04 · recruiting
- NCT05639972 — E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers · Phase 1, PHASE2 · recruiting
- NCT06670495 — HPV Genotype Attribution and Disease Burden of Anal Cancer in China · recruiting
Other National Cancer Institute (NCI) trials
Trials by the same sponsor.
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
- NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00914537 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
- Last refreshed: 6 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00914537.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing